Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.

Expert review of anticancer therapy - 1 Jul 2014

Karachaliou Niki, Rosell Rafael, Morales-Espinosa Daniela, Viteri Santiago

Abstract excerpt

Over a short period of time, translational research has described a new clinically relevant molecular subset of non-small-cell lung cancer (NSCLC) that is defined by EGFR mutations or EML4-ALK fusions. Today, patients with metastatic disease can achieve survival rates at least double that of patients with wild-type tumors. Through the rational dissection of the mechanisms of drug sensitivity and resistance,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Afatinib
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Quinazolinones

Source

Identifiers

PMID: 24611674
DOI: 10.1586/14737140.2014.896210

Genes

ALK
EGFR
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.PMID 24611674Read ↗

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.Semantic proximity Read ↗

Managing Resistance to EFGR- and ALK-Targeted Therapies.Semantic proximity Read ↗

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insightsSemantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Semantic proximity Read ↗

Systemic Therapy for Mutation-Driven NSCLC.Semantic proximity Read ↗

Personalized therapy for lung cancer: striking a moving target.Semantic proximity Read ↗

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read ↗

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Semantic proximity Read ↗

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.